This benefit is rather modest, and the clinical relevance should be evaluated in a long-term outcome study of renal function.
Administration of taxanes in the adjuvant setting improves disease-free survival and overall survival (OS) in early breast cancer, although the absolute survival benefit is rather small across studies (~3 7 %) [ 1– 4].
It's only 0.39″ thick, which is impressive, but when your competitors are only tenths of an inch thicker, the benefits are rather insubstantial (except for bragging rights).
The authors of this meta-analysis noticed that the absolute benefits were rather small 1,000 people have to be treated for 1 year to prevent one death.
However, most studies in animal models do not provide consistent evidence that these drugs can rescue cardiac contractile function, or whether the cardiac benefits are rather a partial consequence of their lipid-lowering action (Table 2) [ 27, 29, 31, 32, 38].
However, despite the statistical significance of the results, the amount of variance explained for the benefit measures was rather small.
Other participants were less critical, but still rather skeptical: Although several personalized therapeutic measures are already applied, their added therapeutic benefit was considered rather small compared to standard interventions: (3) (C) The [classical chemotherapy] is not that much worse in many cases.
One such approach is targeted selective treatment (TST), in which only individual animals that will most benefit are treated, rather than whole groups of at-risk cattle.
Although the overall therapeutic benefit of APC is rather limited, it is clear that PAR1 is an interesting drug target and the identification of other PAR1 activating proteases than thrombin is a priority.
Despite the proven benefits of CDM in uncoded scenarios [6], the benefits of CDM-OFDM aratherher limited when measuring the coded performance in typical operating scenarios conforming to IEEE 802.11a specifications.
